Louise Rodino Klapac Sarepta Therapeutics, Inc. (SRPT) insider trading activity

Louise Rodino Klapac is Head of R&D, CSO of Sarepta Therapeutics, Inc.. Currently has a direct ownership of 67,630 shares of SRPT, which is worth approximately $8.05 Million. The most recent transaction as insider was on Nov 18, 2024, when has been sold 4,558 shares (Common Stock) at a price of $102.89 per share, resulting in proceeds of $468,972. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 67.6K

6.25% 3M change

2.86% 12M change

Total Value Held $8.05 Million

Louise Rodino-Klapac Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 18 2024	SELL Payment of exercise price or tax liability	$468,972 $102.89 p/Share	4,558 Reduced 6.31%	67,630 Common Stock
Jun 24 2024	SELL Payment of exercise price or tax liability	$359,244 $164.64 p/Share	2,182 Reduced 2.94%	72,141 Common Stock
Jun 21 2024	BUY Exercise of conversion of derivative security	-	6,250 Added 7.76%	74,323 Common Stock
Mar 08 2024	SELL Payment of exercise price or tax liability	$111,934 $123.14 p/Share	909 Reduced 1.32%	68,073 Common Stock
Mar 07 2024	SELL Payment of exercise price or tax liability	$61,690 $120.49 p/Share	512 Reduced 0.74%	68,982 Common Stock
Mar 04 2024	SELL Payment of exercise price or tax liability	$216,552 $125.32 p/Share	1,728 Reduced 2.43%	69,494 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$98,175 $126.19 p/Share	778 Reduced 1.18%	65,222 Common Stock
Mar 01 2024	BUY Grant, award, or other acquisition	-	6,000 Added 7.77%	71,222 Common Stock
Nov 17 2023	SELL Payment of exercise price or tax liability	$374,073 $82.98 p/Share	4,508 Reduced 6.42%	65,751 Common Stock
Mar 08 2023	SELL Payment of exercise price or tax liability	$139,709 $153.19 p/Share	912 Reduced 1.28%	70,170 Common Stock
Mar 06 2023	SELL Payment of exercise price or tax liability	$178,276 $157.21 p/Share	1,134 Reduced 1.67%	66,582 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	4,500 Added 5.95%	71,082 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$77,031 $147.57 p/Share	522 Reduced 0.76%	67,716 Common Stock
Nov 17 2022	SELL Payment of exercise price or tax liability	$456,977 $108.52 p/Share	4,211 Reduced 5.83%	67,998 Common Stock
Mar 07 2022	BUY Grant, award, or other acquisition	-	8,000 Added 9.99%	72,111 Common Stock
Mar 04 2022	SELL Payment of exercise price or tax liability	$96,307 $79.2 p/Share	1,216 Reduced 1.86%	64,111 Common Stock
Mar 01 2022	SELL Payment of exercise price or tax liability	$42,929 $75.05 p/Share	572 Reduced 0.87%	65,327 Common Stock
Nov 24 2021	BUY Open market or private purchase	$299,867 $79.33 p/Share	3,780 Added 5.44%	65,678 Common Stock
Nov 16 2021	BUY Grant, award, or other acquisition	-	40,000 Added 39.25%	61,898 Common Stock
Mar 03 2021	BUY Grant, award, or other acquisition	-	15,000 Added 40.36%	22,169 Common Stock

Louise Rodino Klapac

Head of R&D, CSO

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SRPT shares.

Notify only if

Value

Insider Trading

Get notified when an Sarepta Therapeutics, Inc. insider buys or sells SRPT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sarepta Therapeutics, Inc.

Track Activities on SRPT

Account